In another twist to the tale of Starboard Value's push for change at Pfizer, the activist investor has claimed former executives Ian Read and Frank D'Amelio were bullied into lending their
Two former Pfizer executives drawn into a campaign by activist investor Starboard Value to shake up the company have withdrawn their support for the plan.
The week has started with reports that activist investor Starboard Value has amassed a $1 billion stake in pharma group Pfizer and wants strategic changes to restore growth.
Moderna is showcasing its R&D pipeline to investors today, but the headline news is a decision to cut its R&D spend by a massive $1.1 billion a year from 2027, reversing years of gr
BioMarin Pharmaceutical has made a couple of appointments aimed at boosting its pipeline, both internally and externally, with C-suite appointments in charge of R&D and business develop
Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter.